Warenkorb
€ 0,00 0 Buch dabei,
portofrei
Novel Frontiers in the Production of Compounds for Biomedical Use als Buch
PORTO-
FREI

Novel Frontiers in the Production of Compounds for Biomedical Use

'Focus on Biotechnology'. Auflage 2001. Book. Sprache: Englisch.
Buch (gebunden)
Ihr 12%-Rabatt auf alle Spielwaren, Hörbücher, Filme, Musik u.v.m
 
12% Rabatt sichern mit Gutscheincode: SONNE12
 
The present book entitled "Novel Frontiers in the Production of Compounds for Biomedical Uses" can perhaps be placed in its best perspective by the Shakespearean character in The Tempest who exclaimed" What's past is prologue". Indeed, this compilati … weiterlesen
Buch

200,49*

inkl. MwSt.
Portofrei
Lieferbar innerhalb von zwei bis drei Werktagen
Novel Frontiers in the Production of Compounds for Biomedical Use als Buch

Produktdetails

Titel: Novel Frontiers in the Production of Compounds for Biomedical Use

ISBN: 0792367472
EAN: 9780792367475
'Focus on Biotechnology'.
Auflage 2001.
Book.
Sprache: Englisch.
Herausgegeben von Jozef Anné, A. van Broekhoven, Fred Shapiro
Springer Netherlands

28. Februar 2001 - gebunden - 464 Seiten

Beschreibung

The present book entitled "Novel Frontiers in the Production of Compounds for Biomedical Uses" can perhaps be placed in its best perspective by the Shakespearean character in The Tempest who exclaimed" What's past is prologue". Indeed, this compilation of some of the outstanding presentations in the field of biomedicine made at th the 9 European Congress on Biotechnology (Brussels, Belgium, July 11-15, 1999) not only reflects the achievements of the recent past, but provides a privileged glimpse of the biotechnology that is emerging in the first decade of the new Millennium. It is becoming increasingly apparent that biotechnology is offering biomedicine novel approaches and solutions to develop a sorely needed new generation of biopharmaceuticals. This is all the more necessary because in recent years, new diseases have emerged with extraordinary lethality in all corners of the globe, while age-related chronic illnesses have filled the gap wherever biomedicine has made successful inroads. The rise of antibiotic resistance also poses major threats to public health. Thus, as disease patterns evolve, the rational development of new drugs is becoming urgent, not only for the clinical outcome of patients, but also in optimising the allocation of scarce health care resources through the use of cost-effective productions methods. It is in response to all these challenges that biotechnology offers new strategies that go beyond the more traditional approaches. By the mid-1990's, the number of recombinant products approved annually for therapeutic use reached double digits. With the advent of the genomics revolution.

Inhaltsverzeichnis

Editors Preface. Genomics: The New Approach to the Discovery of New Compounds. The genomics approach: is it really the solution? R. Goldschmidt, Karen Bush. The Contribution of Genomics to the Discovery of New Antibiotics; D.J. Holmes, et al. Antibiotics. The antibiotic gallidermin - evolution of a production process; M. Kempf, et al. Resistance to beta-lactams, a self-regenerating problem; J. Aszodi, A. Bryskier. Resistance to aminoglycoside antibiotics: Function meets structure; G.D. Wright, A.M. Berghuis. The genetics and biochemistry of resistance to glycopeptide antibiotics; P.E. Reynolds. beta-Lactamases, an old but ever renascent problem; A. Matagne, et al. Metabolic flux analysis in streptomyces coelicolor; F. Naeimpoor, F. Mavituna. Metabolic engineering of the lysine pathway for beta-lactam overproduction in Penicillium chrysogenum; J. Casqueiro, et al. Glycosylation of antibiotics and other agents from Actinomycetes; W. Piepersberg. Enzymatic synthesis of amoxicillin; A.C. Spiess, V. Kasche. Production of Therapeutic Antibodies. New recombinant bi- and trispecific antibody derivatives; N. Mertens, et al. Advantages of single-domain antigen-binding fragments derived from functional camel heavy-chain antibodies; S. Muyldermans, et al. Heterologous Protein Production: New Production Strategies. Furin as a tool for the endoproteolytic maturation of susceptible recombinant biopharmaceuticals; M. Himmelspach, et al. Development of bioprocesses for the generation of anti-inflammatory, anti-viral and anti-leukaemic agents; M. Mahmoudian. Apoptosis and bioprocess technology; R.P. Singh, A.Al-Rubeai. Gram-positive bacteria as host cells for heterologous production of biopharmaceuticals; L. Van Mellaert, J. Anné. Multiple Pathways of Exoprotein Secretion in Gram-negative bacteria; A.P. Pugsley. Alterations of Metabolic Flux Distributions in Recombinant Escherichia coli in Response to Heterologous Protein Production; J. Weber, U. Rinas. Dynamics of proteolysis and its influence on the accumulation of intracellular recombinant proteins; A. Rozkov, et al. Artificial Organs and Xenografting. The impact of transgenesis and cloning on cell and organ xenotransplantation to humans; L.-M. Houdebine, B. Weill. Reinforced Bioartificial Skin in the Form of Collagen Sponge and Threads; Eun Kyung Yang, et al. Antitumour Compounds. Towards the generation of novel antitumour agents from actinomycetes by combinatorial biosynthesis; J.A. Salas, et al. Cell immobilisation of Taxus media; Chi Wai Tang, F. Mavituna. Pre and Probiotics. The role of prebiotics in human gut microbiology; C.E. Rycroft, et al. The influence of intestinal microflora on mucosal and systemic immune responses; S. Blum, et al. Index.
Servicehotline
089 - 70 80 99 47

Mo. - Fr. 8.00 - 20.00 Uhr
Sa. 10.00 - 20.00 Uhr
Filialhotline
089 - 30 75 75 75

Mo. - Sa. 9.00 - 20.00 Uhr
Bleiben Sie in Kontakt:
Sicher & bequem bezahlen:
akzeptierte Zahlungsarten: Überweisung, offene Rechnung,
Visa, Master Card, American Express, Paypal
Zustellung durch:
* Alle Preise verstehen sich inkl. der gesetzlichen MwSt. Informationen über den Versand und anfallende Versandkosten finden Sie hier.
** Deutschsprachige eBooks und Bücher dürfen aufgrund der in Deutschland geltenden Buchpreisbindung und/oder Vorgaben von Verlagen nicht rabattiert werden. Soweit von uns deutschsprachige eBooks und Bücher günstiger angezeigt werden, wurde bei diesen kürzlich von den Verlagen der Preis gesenkt oder die Buchpreisbindung wurde für diese Titel inzwischen aufgehoben. Angaben zu Preisnachlässen beziehen sich auf den dargestellten Vergleichspreis.